TheraQuest makes appointments
This article was originally published in Scrip
Executive Summary
TheraQuest Biosciences, a US-based clinical-stage pain management company, has named Dr Danny Kao senior vice-president of pharmaceutical development and general counsel and Douglas Baum senior vice-president of business development. Dr Kao previously served as director of strategic development and director of formulation development at Endo Pharmaceuticals, while Mr Baum has been involved in analgesic drug development with Scirex and with its new corporate entity, Premier Research Group.